Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron
The Company also entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (Regeneron) to evaluate IO-108 in combination with Regenerons anti-PD-1 therapy, Libtayo (cemiplimab), as part of its ongoing clinical development program.
- The Company also entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (Regeneron) to evaluate IO-108 in combination with Regenerons anti-PD-1 therapy, Libtayo (cemiplimab), as part of its ongoing clinical development program.
- We are incredibly excited to have enrolled the first patient in an expansion cohort of the IO-108 study.
- The Phase 1 expansion phase includes IO-108 monotherapy cohorts and IO-108 combination cohorts with anti-PD-1 antibodies (pembrolizumab or cemiplimab, depending on tumor types).
- Under the terms of the agreement, Immune-Onc will sponsor and fund the planned clinical trials and Regeneron will provide cemiplimab (Libtayo).